Please login to the form below

Not currently logged in
Email:
Password:

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

Novartis forms coronavirus alliance with life sciences companies

Novartis forms coronavirus alliance with life sciences companies

information. Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and

Latest news

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab). ... Although Novartis and Biogen have so far been able to defend their patents on

  • Novartis launches $20m COVID-19 response fund Novartis launches $20m COVID-19 response fund

    Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and therapeutics

  • Biogen joins COVID-19 efforts with $10m support fund Biogen joins COVID-19 efforts with $10m support fund

    Funds will be used to address 'immediate critical needs'. Biogen has committed $10m in support of global response efforts and communities who have been affected by the COVID-19 pandemic. ... Biogen also said that it will be supporting the Massachusetts

  • UK officially moves into ‘delay’ phase of coronavirus plan UK officially moves into ‘delay’ phase of coronavirus plan

    Meanwhile, across the Atlantic in the US, an outbreak of the coronavirus is snowballing in Cambridge, Massachusetts after a number of employees from Biogen tested positive for the virus. ... As of Thursday, cases had increased to 108 in the state, of

  • Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

    Biogen has made another big investment play in Alzheimer’s disease, penning a $350m upfront agreement with gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part ... The licensing deal comes as Biogen prepares to file its

More from news
Approximately 120 fully matching, plus 305 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 43 partially matching documents found.

Latest appointments

More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    Strategic planning - to ensure sustained engagement and ongoing success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, HRA Pharma, Janssen, Leo Pharma, Mylan,

  • Article: Market access in Brazil

    In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde

  • Healthcircle Healthcircle

    Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.

  • Attigo (part of the Mednet Group) Attigo (part of the Mednet Group)

    Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.

  • IGNIFI IGNIFI

    Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics